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Abstract 
Background: Multidrug resistance is one of the major reasons chemotherapy-based treatments failed in hepatitis B 
virus (HBV) related hepatocellular carcinoma (HCC). Hypoxia is generally associated with tumor chemo-resistance. The 
aim of the study was to investigate the effect of Arsenic trioxide (As2O3) on the hypoxia-induced chemo-resistance to 
5-FU or cisplatin and explored its underlying mechanism in the HBx-HepG2 cells.
Methods: MTT assay was used to examine the cell viability. Mitochondrial membrane potential (MMP) and cell cycle 
was examined by flow cytometry. qRT-PCR was employed to observe the mRNA expression level; and western blot 
assay was used to determine the protein expression level.
Results: Our results showed that transfection of HBx plasmid established the HBx-HepG2 cells expressing HBx, 
and the expression of HBx was confirmed by qRT-PCR and western blot. Exposure of HBx-HepG2 cells to hypoxia 
(5 % O2, 3 % O2, 1 % O2) for 48 h increased the chemo-resistance to 5-fluorouracil (5-FU) (50–1600 µM) and cisplatin 
(25–800 µM), reduced MMP, and caused the cell cycle arrest at G0/G1 phase in a concentration-dependent manner. 
Hypoxia also concentration-dependently (5 % O2, 3 % O2, 1 % O2) reduced mRNA expression level of P-glycoprotein 
(P-gp), multidrug resistance protein (MRP1), lung resistance protein (LRP), and decreased the protein expression level 
of hypoxia-inducible factor-1α (HIF-1α), P-gp MRP1, and LRP. Following pretreatment with As2O3 at a non-cytotoxic 
concentration re-sensitized the hypoxia (1 % O2)-induced chemo-resistance to 5-FU and cisplatin in HBx-HepG2 cells. 
As2O3 pretreatment also prevented MMP reduction and G0/G1 arrest induced by hypoxia. Meanwhile, As2O3 antago-
nized increase of HIF-1α protein induced by hypoxia, and it also suppresses the increase in expression levels of P-gp, 
MRP1, and LRP mRNA and proteins. In addition, As2O3 in combination with 5-FU treatment caused up-regulation of 
DR5, caspase 3, caspase 8, and caspase 9, and down-regulation of BCL-2, but had no effect of DR4.
Conclusions: Our results may suggest that As2O3 re-sensitizes hypoxia-induced chemo-resistance in HBx-HepG2 via 
complex pathways, and As2O3 may be a potential agent that given in combination with other anti-drugs for the treat-
ment of HBV related HCC, which is resistant to chemotherapy.
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Background
Hepatitis-B-virus (HBV)-related hepatocellular carci-
noma (HCC) is among the most common cancers in the 
world and is also the most frequent cause of death from 
this malignancy [1]. Although the precise mechanism 
underlying the development of HCC is unclear, several 
studies have shown that hepatitis virus X protein (HBx) 
plays a key role in the pathogenesis of HCC [2, 3]. HBx 
demonstrates its oncogenic potential in transgenic model 
[4]. In addition, HBx affects both mitochondria/caspase 
family and the cell-cycle check proteins [5–7].
HCC is characterized by a high degree of multidrug 
resistance (MDR) [8]. In clinic, it has been found that 
part of HCC patients exhibited MDR even during the 
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course of initial chemotherapy instead of after repeated 
chemotherapy, which suggests that MDR might be the 
nature of some HCC. However, the detailed molecular 
mechanisms of MDR are largely unknown, and studies 
have shown that chemo-resistant solid tumors depend on 
the actions of drug transporter proteins, including P-gly-
coprotein (P-gp), multidrug resistance protein (MRP1), 
lung resistance protein (LRP) and others, which export 
actively most anticancer drugs to decrease intracellular 
drug accumulation from tumor cells [9, 10].
The microenvironment around rapidly growing HCC is 
associated with increase oxygen consumption and rela-
tively diminished blood supply, which results in promi-
nent hypoxia of focal areas [11]. Hypoxia has been shown 
to enhanced tumor progression in HCC [12]. Hypoxia-
inducible factor-1 (HIF-1) has been shown to an impor-
tant mediator of hypoxia-regulated gene expression, and 
it can activate the transcription of genes that are involved 
in key aspects of cancer biology, including cell viability, 
invasion, metastasis, and angiogenesis [13–15].
Arsenic trioxide (As2O3) has shown promising results 
in the treatment of many hematopoietic malignancies. In 
the 1970s, Chinese physicians began to use As2O3 to treat 
actue promyelocytic leukemia (APL) with great success 
[16, 17]. Although the detailed molecular mechanisms 
of arsenic trioxide are not clarified, results in various 
studies have showed that As2O3 involves in induction of 
apoptosis, partial cellular differentiation, degradation of 
specific APL fusion transcripts, anti-proliferation, gen-
eration of reactive oxygen species [18, 19]. Recent stud-
ies also demonstrated that As2O3 reduces drug resistance 
to adriamycin in leukemic K562/A02 cells via multiple 
mechanisms [20], and arsenic trioxide eliminates the dif-
ferential chemo-resistance in B cell lymphoma cells via 
the overexpression of p28 [21]. Another study showed 
that As2O3 re-sensitized cells to 5-fluorouracil (5-FU) in 
5-FU-resistant colorectal cancer cell line via suppression 
of thymidylate synthase [22]. In the HCC, As2O3 potenti-
ates the anti-cancer activities of sorafenib via inhibiting 
Akt activation [23]. Studies also demonstrated that As2O3 
reduced chemo-resistance via inducing apoptosis in can-
cer cell lines [24], and the apoptosis induced by As2O= 
has been suggested to be mediated by tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) [25], 
which is important in regulating the apoptotic signaling 
pathways [26–29]. For instance, As2O3-mediated growth 
inhibition of myeloma cells is associated with an extrin-
sic or intrinsic signaling pathway through activation of 
TRAIL or TRAIL receptor two [30] and another line of 
study demonstrated that As2O3 sensitizes human glioma 
cells to TRAIL-induced apoptosis via CCAAT/enhancer-
binding protein homologous protein-dependent DR5 
up-regulation [31]. However, whether As2O3 could 
re-sensitize the chemo-resistant HBV-related HCC to 
anti-cancer drugs is still unknown.
In the present study, we first established the stable 
HepG2 cell lines expressing HBx. Then, we determined 
the hypoxia conditions, which induce chemo-resistance 
to 5-FU and cisplatin by using MTT assay. The effects 
of different hypoxia conditions on MMP and cell cycle 
were also examined by using flow cytometry. qRT-PCR 
and western blot assay were used determine the effect 
of hypoxia treatment on the expression levels of HIF-1α, 
P-gp, MRP1, and LRP. We also investigated if pretreat-
ment of As2O3 could re-sensitize the hypoxia-induced 
chemo-resistance in HBx-HepG cells, and also examined 
its effect on MMP, cell cycle as well as the expression lev-
els of HIF-1α, P-gp, MRP1, and LRP. Finally, we examined 
the effect of As2O3 in combination with 5-FU treatment 
on apoptotic signaling pathway.
Methods
Cell culture
The cells of HepG2 (American Type Culture Collection, 
USA) and HepG2.2.15 (constitutively replicate HBV) 
(Shanghai Second Military Medical University), were 
cultured in Dulbecco’s modified Eagle medium (DMEM) 
with 10  % fetal bovine serum (Life Technologies Inc, 
Gaithersburg, MD, USA). Cell were incubated at 37 °C in 
a humidified atmosphere with 5 % CO2.
Generation of stable HepG2 cell lines expressing HBx
The HBV X gene was amplified from plasmid pIERES2-
EGFP-HBV by PCR. The purified HBx gene fragment was 
inserted into a lentivirus vector (pZac2.1). HepG2 cells 
were then transfected with the packaged recombinant 
lentivirus, and resistant cell clones were selected with 
puromycin. The expression of HBx was examined using 
qRT-PCR and Western blot.
Establishment of hypoxia model and drug treatment
Cells were cultured under normoxia condition for 24  h 
and subsequently were culture under normoxic (21  % 
O2, 5 % CO2, 74 % N2) or hypoxic condition (5 % O2, 5 % 
CO2, 90 % N2; 3 % O2, 5 % CO2, 92 % N2; or 1 % O2, 5 % 
CO2, 94 % N2) for 48 h in the tris-air incubator (NU4950, 
NUAIRE company, USA).
MTT assay
Cells were plated at 5000 cells per well in 96-well plates. 
After culture for 24  h under normoxic conditions, cells 
were exposed to normoxic (21 % O2) or hypoxic (5 % O2, 
3 % O2, or 1 % O2) conditions for 48 h. Cells were then 
treated with relevant doses of 5-FU (0, 50, 100, 200, 400, 
800, 1600  μM) and cisplatin (0, 25, 50, 100, 200, 400, 
800 μM) for 24 h. In another set of experiment, 48 h after 
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hypoxia treatment, cells were pretreated with As2O3 for 
24  h, and then treated with relevant doses of 5-FU (0, 
50, 100, 200, 400, 800, 1600 μM) and cisplatin (0, 25, 50, 
100, 200, 400, 800 μM) for 24 h. Subsequently, cells were 
incubated for 4  h in the presence of the MTT reagent 
and then lysed with acidified isopropanol. Absorbance 
was measured at 570 nm. Cell survival rate (cell viability) 
was calculated as the absorbance value of the test group/
absorbance value of the control group X 100 %.
RNA extraction, reverse transcription PCR and qRT‑PCR 
analysis
Forty-eight hour after hypoxia (5 % O2, 3 % O2 or 1 % O2) 
treatment, or 48 h after hypoxia (1 % O2) treatment fol-
lowed by As2O3 treatment for 24 h, total RNA fractions 
were isolated from HBx-HepG2 cells and HepG2.2.15 
cells using TRIzol reagent (Invitrogen, CA, USA). qRT-
PCR was performed with SYBR Premix Ex Taq (TaKaRa). 
GAPDH was used as an internal control for mRNA. The 
relative quantitative analysis of data was performed using 
7000 system SDS software v1.2.3 (Applied Biosystems). 
The relative quantitation of target gene expression was 
obtained using the comparative ΔΔCT method.
Flow cytometry
Forty-eight hour after hypoxia (5 % O2, 3 % O2 or 1 % O2) 
treatment, or 48 h after hypoxia (1 % O2) treatment fol-
lowed by As2O3 treatment for 24 h, cells were subject to 
cell cycle and MMP analysis.
For the analysis of MMP, the cells were harvested 
and washed with ice cold PBS twice by centrifugation 
at 1000 rpm for 10 min, and then 0.5 ml PBS contained 
10 µg/ml Rho-123 was added to the cells. The tubes were 
vortexed gently and incubated at 37  °C in the dark for 
30  min, then were washed with ice-cold PBS twice by 
centrifugation at 1000  rpm for 10  min. 0.5  ml PBS was 
added to the cells. Flow cytometric analysis was carried 
out by FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA, USA).
For cell cycle analysis, cells were fixed with 75 % eth-
anol at 4  °C overnight and washed with cold PBS and 
treated with RNaseI, followed by a 30 min staining with 
propidium iodide in dark. Cell cycle distributors were 
analyzed by a FACSCalibur flow cytometer (BD Bio-
sciences, San Jose, CA, USA).
Western blot analysis
Forty-eight hour after hypoxia (5 % O2, 3 % O2 or 1 % O2) 
treatment, or 48 h after hypoxia (1 % O2) treatment fol-
lowed by As2O3 treatment for 24 h, and in the apoptosis 
study, cells were further treated with 5-FU for another 
24  h, cells were subject to western blot assay. Proteins 
were extracted from whole cell lysates and separated 
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, then transferred to a polyvinylidene fluoride 
(PVDF) membrane. The following primary antibodies 
were used: mouse-anti-HBx (1:1000; Abcam, Cambridge, 
MA, USA); rabbit anti-HIF-1α (1:1000; Abcam, Cam-
bridge, MA, USA); rabbit anti-P-gp (1:500; Abcam, Cam-
bridge, MA, USA); rabbit-anti-MRP1 (1:1500; Abcam, 
Cambridge, MA, USA); rabbit-anti-LRP (1:500; Santa 
Cruz Biotechnology, Dallas, TX, USA); rabbit-anti-death 
receptor 4 (DR4) (1:500; Abcam, Cambridge, USA); 
rabbit-anti-death receptor 5 (DR5) (1:1000; Abcam, 
Cambridge, MA, USA); rabbit-anti-BCL-2 (1:1500; 
Abcam, Cambridge, MA, USA); rabbit-anti-caspase-3 
(1:300, Santa Cruz Biotechnology, Dallas, Texas, USA); 
rabbit-anti-caspase-8 (1:2000, Santa Cruz Biotechnol-
ogy, Dallas, Texas, USA); rabbit-anti-caspase-9 (1:1000, 
Abcam, Cambridge, MA, USA); and mouse anti-β-actin 
(1: 5000; Abcam, Cambridge, MA, USA). Membranes 
were then incubated with the horseradish peroxidase-
conjugated secondary anti-bodies (1:2000; Abcam, Cam-
bridge, MA, USA). The membranes were exposed and 
with the Image J program (Bio-Rad).
Statistical analysis
All statistical analysis was carried out using GraphPad 
Prism version 6 (GraphPad Prism version 6.0, Inc., San 
Diego, CA, USA). The differences among groups were 
analyzed by one-way ANOVA followed by Bonferroni’s 
multiple comparison tests or t-test, as appropriate. All 
data are expressed as mean  ±  s.e.m. Differences were 
considered significant when P < 0.05.
Results
Generation of HBx‑HepG2 cell lines
After transfecting the HepG2 cells with HBx plasmid or 
empty vector, qRT-PCR and western blot results showed 
that HBx mRNA and protein were expressed in the HBx-
transfected HepG2 cell lines, and the expression levels 
of HBx mRNA and protein were similar to that in posi-
tive control, HepG2.2.15 cells, which stably expressed the 
whole HBV genome; no HBx expression were found in 
the HepG2 cells transfected with empty vector (Fig. 1).
Effect of hypoxia on chemo‑sensitivity
The chemo-sensitivity of the HBx-HepG2 cells to 5-FU 
(50–1600 μM) and cisplatin (25–800 μM) was evaluated 
under normoxic or hypoxic conditions using the MTT 
assay. 5-FU (50–1600  μM) and cisplatin (25–800  μM) 
dose-dependently reduced the cell viability under nor-
moxic condition (21 % O2).
Exposure of HBx-HepG2 cells to hypoxia (5  % O2) 
for 48  h did not significantly affect the chemo-sen-
sitivity to 5-FU and cisplatin (P > 0.05; n = 4, Fig. 2a, 
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b); Exposure of HBx-HepG2 cells to hypoxia (3  % O2) 
for 48  h significantly increased the chemo-resistance 
to 5-FU and cisplatin at dose of 800- 1600  μM and 
800 μM, respectively, (P < 0.05; n = 4, Fig. 2a, b); Expo-
sure of HBx-HepG2 cells to hypoxia (1 % O2) for 48 h 
also significantly increased the chemo-resistance to 
5-FU and cisplatin with much larger dose ranges (100–
1600 μM for 5-FU; 50–800 μM for cisplatin) (P < 0.05; 
n = 4, Fig. 2a, b).
Effect of hypoxia on MMP
Mitochondria involve in the process of apoptosis and 
necrosis in different ways and the MMP reflects the func-
tion of mitochondria. To examine the effect of hypoxia 
on MMP, we assessed the changes of MMP using rhoda-
mine 123 (Rho-123). Flow cytometry showed that MMP 
Fig. 1 Establishment of HepG2-HBx cell lines. qRT-PCR and western 
blot were used to evaluate the expression levels of HBx mRNA and 
protein in empty vector-transfected HepG2 cells, HBx-transfected 
HepG2 cells and HepG2.2.15 cells. All data were expressed as 
mean ± s.e.m., n = 4
Fig. 2 Effect of hypoxia on the cell viability of HBX-HepG2 cells 
treated with chemotherapeutic agents and on the mitochondrial 
membrane potential (MMP) in HBX-HepG2 cells. MTT assay was 
conducted on HBX-HepG2 cells pre-incubated for 48 h in normoxic 
(21 % O2) or hypoxic (5 % O2, 3 % O2, or 1 % O2) conditions and subse-
quently treated with a 5-FU (50–1600 µM) or b Cisplatin (25–800 µM); 
c flow-cytometry was conducted on HBx-HepG2 cells pre-incubated 
for 48 h in normoxic (21 % O2) or hypoxic (5 % O2, 3 % O2, or 1 % 
O2) conditions to measure the MMP. All data were expressed as 
mean ± s.e.m., n = 4; significant differences between hypoxia 
(1 % O2) group and normoxia group were indicated as *P < 0.05, 
**P < 0.01, ***P < 0.001; significantly differences between hypoxia 
(3 % O2) group and normoxia group were indicated as 
#P < 0.05 (One-
way ANOVA followed by Bonferroni’s multiple comparison tests)
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was not affected in HBx-HepG2 cells exposed to hypoxia 
(5 % O2) for 48 h compared with the normoxia (21 % O2) 
group (P > 0.05; n = 4, Fig. 2c). Exposure of hypoxia (3 % 
O2 or 1 % O2) for 48 h significantly decreased the MMP 
in HBx-HepG2 cells compared with normoxia (21 % O2) 
group, and exposure of hypoxia (1 % O2) for 48 h showed 
about 50 % reduction of MMP compared with normoxia 
(21 % O2) group (P < 0.05; n = 4, Fig. 2c).
Effect of hypoxia on cell cycle
The effect of different hypoxic conditions on cell cycle 
of HBx- HepG2 were analyzed by flow cytometry. Our 
results showed that exposure of HBx-HepG2 cells to 
hypoxia (5  % O2) for 48  h did not significantly affect 
the cell cycle (Table 1); exposure of HBx-HepG2 cells to 
hypoxia (3 % O2) for 48 h significantly increased percent-
age of G0/G1 phase compared with normoxia (21 % O2) 
group (63.7 vs. 60.2 %; Table 1); exposure of HBx-HepG2 
cells to hypoxia (1 % O2) for 48 h significantly increased 
percentage of G0/G1 phase compared with normoxia 
(21  %, O2) group (67.9 vs. 60.2  %; Table  1), also with a 
concomitant decrease in the percentage of cells in the S 
phase (11.8 vs. 20.3 %; Table 1) and G2/M phase (7.0 vs. 
14.6 %; Table 1).
Effect of hypoxia on expression of MDR related genes 
and proteins
qTR-PCR was used to determine the expression of P-gp, 
MRP1, and LRP mRNA in HBx-HepG2 cells pre-incu-
bated in normoxic (21 % O2) or hypoxia (5 % O2, 3 % O2, 
or 1  % O2) conditions for 48  h. Hypoxia exposure con-
centration-dependently (from 5 to 1 % O2) increased the 
expression levels of P-gp, MRP1, and LRP mRNA in HBx-
HepG2 cells (P < 0.05;n = 4, Fig. 3) with hypoxia(1 % O2) 
causing about 6.5 fold, 3.5 fold and 5.0 fold increase of 
P-gp, MRP1, and LRP mRNA (P < 0.05; n = 4, Fig. 3).
We further used western blot assay to examine the 
effect of hypoxia on the expression of HIF-1 α, P-gp, 
Table 1 Effect of  Hypoxia on  the cell cycle of  HBX-HepG2 
cells
All data were expressed as mean ± s.e.m., n = 4; significant differences between 
hypoxia (1% O2) group and normoxia (21% O2) group were indicated as  
* P < 0.05, ** P < 0.01; significant differences between hypoxia (3% O2) group 
and normoxia (21% O2) group were indicated as 
# P < 0.05 (One-way ANOVA 
followed by Bonferroni’s multiple comparison tests)
Sub G1 G0/G1 S G2/M
Normoxia 1.1 ± 0.4 60.2 ± 9.2 20.3 ± 3.7 14.6 ± 4.3
Hypoxia (5 %) 1.3 ± 1.1 61.5 ± 10.3 19.5 ± 6.8 14.5 ± 2.9
Hypoxia (3 %) 5.5 ± 3.3 63.7 ± 8.7# 17.5 ± 6.5 13.2 ± 2.3
Hypoxia (1 %) 12.9 ± 6.6 67.9 ± 11.2** 11.8 ± 4.9* 7.0 ± 5.5*
Fig. 3 Effect of hypoxia on expression levels of P-gp, MRP1 and LRP 
mRNA inHBX-HepG2 cells. qRT-PCR assay was conducted on HBx-
HepG2 cells pre-incubated for 48 h in normoxic (21 % O2) or hypoxic 
(5 % O2, 3 % O2, or 1 % O2) to measure the expression levels of a P-gp, 
b MRP1 and c LRP mRNA. All data were expressed as mean ± s.e.m., 
n = 4; significant differences between hypoxia (1 % O2) group and 
normoxia group were indicated as **P < 0.01, ***P < 0.001; significant 
differences between hypoxia (3 % O2) group and normoxia group 
were indicated as #P < 0.05; ##P < 0.01 (One-way ANOVA followed by 
Bonferroni’s multiple comparison tests)
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MRP1, and LRP protein in HBx-HepG2 cells. The west-
ern blot results showed that hypoxia also concentration-
dependently (from 5 to 1 % O2) increased the expression 
levels of P-gp, MRP1, and LRP protein in HBx-HepG2 
cells (P < 0.05; n = 4, Fig. 4) with hypoxia (1 % O2) having 
the most profound effect on the increased expression of 
P-gp, MRP1, and LRP protein (P < 0.05; n = 4, Fig. 4).
As2O3 re‑sensitized hypoxia‑induced resistance to 5‑FU 
and cisplatin in HBx‑HepG2 cells
Effects of As2O3 on hypoxia-induced resistance to 5-FU 
and cisplatin in HBx-HepG2 cells were evaluated by 
MTT assay. Pretreatment of As2O3 (1 μM) for 24 h alone 
did not significantly reduced the cell viability (data not 
shown). As2O3 pretreatment for 24  h and subsequent 
5-FU (50–1600 µM) or cisplatin (25–800 μM) treatment 
significantly reduced the cell viability in HBx-HepG2 pre-
incubated in hypoxia (1  % O2) for 48  h, compared with 
treatment of 5-FU or cisplatin alone (P  <  0.05; n  =  4, 
Fig. 5a, b).
Effect of AsO3 on MMP and cell cycle in HBx‑HepG2 cells
To further investigate the mechanisms of As2O3 on the 
hypoxia-induced chemo-resistance, flow cytometry 
was used to determine the MMP and cell cycle in HBx-
HepG2 cells. Pretreatment of As2O3 for 24 h significantly 
increased the MMP in HBx-HepG2 cells pre-incubated 
in hypoxia (1  % O2) for 48  h compared with control 
(P  <  0.05; n  =  4, Fig.  5c). In addition, pretreatment of 
As2O3 for 24 h significantly decreased the percentage of 
cells in G0/G1 phase with an associated increase in the 
percentage of cells in S and G2/M phase in HBx-HepG2 
cells pre-incubated in hypoxia (1  % O2) for 48  h com-
pared with control (P < 0.05; n = 4, Fig. 5d).
Effect of As2O3 on expression of MDR related genes 
and proteins
To investigate if As2O3 pretreatment altered the expres-
sion of MDR related genes and proteins, qRT-PCR was 
employed to determine expression levels of P-gp, MRP1 
and LRP mRNA, and western blot assay was used to 
measure the expression levels of HIF-1α, P-gp, MRP1, 
and LRP proteins. Our qRT-PCR results showed that 
As2O3 pretreatment significantly decreased the expres-
sion levels of P-gp, MRP1 and LRP mRNA in HBx-HepG2 
cells pre-incubated in hypoxia (1  % O2) for 48  h when 
compared with control (P < 0.05; n = 4, Fig. 6). Western 
blot results further confirmed that As2O3 pretreatment 
Fig. 4 Effect of hypoxia on expression levels of HIF-1α, P-gp, MRP1 and LRP protein in HBx-HepG2 cells. Western blot assay was conducted on 
HBX-HepG2 cells pre-incubated for 48 h in normoxic (21 % O2) or hypoxic (5 % O2, 3 % O2, or 1 % O2) conditions to measure the expression levels 
of HIF-1α, P-gp, MRP1 and LRP protein, band densities were normalized to β-actin. All data were expressed as mean ± s.e.m., n = 4; significant differ-
ences between hypoxia (1 % O2) group and normoxia group were indicated as *P < 0.05, **P < 0.01; significantly differences between hypoxia (3 % 
O2) group and normoxia group were indicated as 
#P < 0.05 (One-way ANOVA followed by Bonferroni’s multiple comparison tests)
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significantly down-regulated the expression of HIF-1α, 
MRP1, and LRP proteins in HBx-HehpG2 cells pre-incu-
bated in hypoxia (1 % O2) for 48 h compared with control 
(P < 0.05; n = 4, Fig. 7).
Effect of As2O3 in combination with 5‑FU treatment 
on expression of apoptotic‑related factors
To investigate how the apoptotic signaling pathway is 
affected by As2O3 in combination with 5-FU treatment, 
western blot assay was used to determine the protein 
expression levels of apoptotic-related factors. The 
combinational treatment significantly increased the 
expression protein levels of DR5, caspase 3, caspase 8, 
and caspase 9 (P  <  0.05; n =  4, Fig.  8), and decreased 
the protein expression level of BCL-2 (P < 0.05; n = 4, 
Fig. 8); but had no effect on the protein expression level 
of DR4 (Fig. 8).
Discussion
In the present study, we for the first time investigated the 
effect of As2O3 on the hypoxia-induced chemo-resistance 
to 5-FU or cisplatin in HBx-HepG2 cells. Generation of 
stable HepG2 cells expressing HBx was carried out by 
transfection of HBx plasmid, and the expression of HBx 
in HepG2 cells after transfection was further confirmed 
by qRT-pCR and western blot assays. After generation of 
HBx-HepG2cells, we moved to examine different hypoxic 
(5  % O2, 3  % O2, or 1  % O2) conditions on the chemo-
sensitivity to 5-FU or cisplatin in HBx-HepG2 cells. 5-FU 
and cisplatin are widely used as first-line and second-line 
chemotherapy for metastatic HCC [32]. However, the 
results still remain poor in advanced cases, especially 
those with metastatic lesions, often dependent on the 
acquisition of resistance to therapy. The hypoxic environ-
ment in the central area of the growing tumor, dependent 
Fig. 5 Effect of As2O3 (1 µM) on chemo-sensitivity, MMP, and cell cycle of HBx-HepG2 cells pretreated with hypoxia (1 % O2). MTT assay was used 
to evaluate the effect of As2O3 on chemo-sensitivity to a 5-FU (50–1600 µM) or b cisplatin (25–800 µM) in HBx-HepG2 cells pretreated with 48 h 
hypoxia (1 % O2); c flow-cytometry was used to examine the effect of As2O3 on MMP in HBx-HepG2 cells pretreated with 48 h hypoxia (1 % O2); d 
flow-cytometry was used to examine the effect of As2O3 on MMP in HBx-HepG2 cells pretreated with 48 h hypoxia (1 % O2). All data were expressed 
as mean ± s.e.m., n = 4; ATO = As2O3; significant differences between hypoxia (1 % O2) group and hypoxia (1 % O2) + ATO group were indicated as 
*P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t-test)
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on the insufficient neovascularization, seems to be in 
part responsible for this phenomenon. In fact, hypoxic 
cells are known to be more resistant to ionizing radia-
tion and chemotherapy [33]. Both 5-FU and cisplatin 
concentration-dependently inhibited the cell viability of 
HBx-HepG2 cells under normoxia, but under hypoxia 
particularly at 1  % O2, the inhibitory effects of agents 
were significantly abrogated. Our results showed also 
that hypoxia (3  % O2 and 1  % O2) enhanced the arrest 
of cell cycle at G0/G1 phase, and previous studies have 
also demonstrated hypoxia altered the cell cycle at G0/
G1 phase in different types of cancer cells. For instance, 
hypoxia (1 % O2) enhanced the arrest of cell cycle at G0/
G1 phase in colorectal cancer cell lines, which showed 
chemo-resistance to 5-FU and oxaliplatin [34]. Stud-
ies using HepG2 cells also found that hypoxia (1  % O2) 
induced chemo-resistance with an associated arrest 
of cell cycle at G0/G1 phase [35]. However, the effect of 
hypoxia on cell arrest of G0/G1 phase in HBx-HepG2 cells 
has been not shown yet, and our results may indicate that 
chemo-resistance to 5-FU and cisplatin in HBx-HepG2 
cells was partly dependent on the arrest of the cell cycle 
at G0/G1 phase, induced by hypoxia, which seemed to 
prevent these agents from fully exerting their effects on 
the cell cycle.
Mitochondria have been found to participate in the 
process of hypoxic responses in different ways and the 
MMP can reflect the function of mitochondria [36]. 
Hypoxia could decrease electron-transport rate deter-
mining MMP reduction, increased ROS generation, 
and enhanced NO synthase [37]. In the present study, 
we demonstrated that hypoxia reduced the MMP in 
a concentration-dependent manner. Previous studies 
also showed that hypoxia could reduce the MMP in the 
human umbilical cord vein endothelial cells [36]. The 
reduction of MMP has been linked to the upregulation 
of HIF-1α protein [37]. It was demonstrated in this study 
that hypoxia significantly increased the HIF-1α protein 
expression. The upregulation of HIF-1α has been well 
documented in various studies. Studies also indicate that 
HIF-1α, as a nuclear transcript factor, facilities the tran-
scription of the MDR related genes and thus accelerates 
the synthesis of drug transporter proteins including P-gp, 
MRP1, and LRP, which functions as drug transporter to 
reduce intracellular drug accumulation [38–40]. Here, 
we also confirmed that hypoxia increased the expres-
sion levels of P-gp, MRP1 and LRP mRNA and protein in 
HBx-HepG2 cells. It is possible that upregulation of these 
MDR related genes and proteins is via the HIF-1α path-
way. However, further studies may be required to known 
Fig. 6 Effect of As2O3 (1 µM) on the expression levels of P-gp, MRP1 
and LRP mRNA inHBx-HepG2 cells pretreated with hypoxia (1 % 
O2). qRT-PCR assay was used to examine the effect of As2O3 on the 
expression levels of a P-gp, b MRP1 and c LRP mRNA in HBx-HepG2 
cells pretreated with hypoxia (1 % O2). All data were expressed as 
mean ± s.e.m., n = 4; significantly differences between hypoxia 
(1 % O2) group and hypoxia (1 % O2) + ATO group were indicated as 
*P < 0.05, **P < 0.01 (unpaired t-test)
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down the HIF-1α or overexpress HIF-1α to confirm the 
role of HIF-1α in the regulation of MDR related genes 
and proteins in HBx-HepG2 cells.
We then tested if As2O3 pretreatment could re-sen-
sitize the hypoxia-induced chemo-resistance to 5-FU 
and cisplatin and explored its underlying mechanism in 
the HBx-HepG2 cells. Our results showed that follow-
ing pretreatment with As2O3 at a non-cytotoxic con-
centration re-sensitize the hypoxia (1  % O2)-induced 
chemo-resistance to 5-FU and cisplatin in HBx-HepG2 
cells. As2O3 pretreatment could also prevent MMP 
reduction and G0/G1 arrest induced by hypoxia. Mean-
while, As2O3 antagonized increase of HIF-1α protein 
induced by hypoxia, and it also suppresses the increase 
in expression levels of P-gp, MRP1, and LRP mRNA and 
proteins. The mechanisms of As2O3 re-sensitize chemo-
resistance has been proposed in several studies. Zhao 
et  al., demonstrated As2O3 significantly decreased the 
expression of GST-π and decreased expression of Topo-
II, which indicated these MDR-related enzymes may be 
contributed to the partial reverse of MDR induced by 
As2O3 in K563/A02 cells [20]. Another line of evidence 
suggested that As2O3 eliminated chemo-resistance in 
murine B-cell lymphoma via the overexpression of p28 
[21]. Recent study also showed that As2O3 inhibited 
the expression of Bcl-2 and Bcl-xL, and increased the 
expression of Bax in HCC cells, which in turn enhances 
sorafenib-induced apoptosis in HCC [23]. Our results 
may suggest that As2O3 re-sensitizes chemo-resistance 
may involve the mitochondrial function changes and 
the alteration of HIF-1α in HBx-HepG2 cells, and other 
pathway may be also involved, which requires further 
investigation. In addition, we also found that As2O3 
in combination with 5-FU treatment could activate 
Fig. 7 Effect of As2O3 (1 µM) on the expression levels of P-gp, MRP1 and LRP protein in HBx-HepG2 cells pretreated with hypoxia (1 % O2). Western 
blot assay was used to examine the effect of As2O3 on the expression levels of P-gp, MRP1 and LRP protein in HBx-HepG2 cells pretreated with 
hypoxia (1 % O2), band densities were normalized to β-actin. All data were expressed as mean ± s.e.m., n = 4; significant differences between 
hypoxia (1 % O2) group and hypoxia (1 % O2) + ATO group were indicated as *P < 0.05, **P < 0.01 (unpaired t-test)
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caspase-related apoptotic signaling pathway possibly 
via the up-regulation of DR5, which may suggest As2O3 
re-sensitizes chemo-resistance at least owing to up-reg-
ulation of DR5, caspase 3, caspase 8, and caspase 9, and 
down-regulation of BCL-2. It is also of great interest to 
investigate if other signaling pathway is also involved in 
the future studies.
Cyclin D1 is a key factor for driving the G1/S transi-
tion of cell cycle, and is overexpressed in HBV-HCC tis-
sues [41, 42]. Studies showed that As2O3 synergized with 
sorafenib to down-regulate the expression on of cyclin 
D1, resulting in cell arrested at G0/G1 in HCC cells [23], 
and our results may suggest that As2O3 re-sensitized hpy-
oxia chemo-resistance via down-regulation of cyclin D1, 
which results in cell cycle arrest at G0/G1 in HBx-HepG2 
cells. The role cyclin D1 in As2O3-induced cycle cell 
changes may require further investigation.
In conclusion, our results may suggest that As2O3 re-
sensitizes hypoxia-induced chemo-resistance in HBx-
HepG2 via complex pathways, and As2O3 may be a 
potential agent that given in combination with other anti-
drugs for the treatment of HBV related HCC, which is 
resistant to chemotherapy.
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